Islet Cell Transplant for Type 1 Diabetes

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 16, 2013

Primary Completion Date

October 16, 2025

Study Completion Date

October 16, 2025

Conditions
Type 1 Diabetes Mellitus
Interventions
BIOLOGICAL

Allogenic Human Islet Cells

Intraportal (into the liver) infusion of islet cells, with a maximum of three islet transplants.

DRUG

Immunosuppressive Agents

Anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets.

DRUG

Gastrin 17

Gastrin-17 (or GAST-17) - a gut hormone injected under the skin for 30 days (optional treatment for islet dysfunction).

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

University of California, Los Angeles

OTHER

lead

City of Hope Medical Center

OTHER

NCT01909245 - Islet Cell Transplant for Type 1 Diabetes | Biotech Hunter | Biotech Hunter